51
|
Rovira-Llopis S, Díaz-Morales N, Bañuls C, Blas-García A, Polo M, López-Domenech S, Jover A, Rocha M, Hernández-Mijares A, Víctor VM. Is Autophagy Altered in the Leukocytes of Type 2 Diabetic Patients? Antioxid Redox Signal 2015; 23:1050-1056. [PMID: 26218267 DOI: 10.1089/ars.2015.6447] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
It is unknown whether autophagy is altered in the leukocytes of type 2 diabetes (T2D) patients and whether oxidative and endoplasmic reticulum (ER) stresses regulate this mechanism. We studied anthropometric and metabolic parameters and evaluated oxidative stress, chromatin condensation, ER stress, and autophagy parameters in leukocytes of 103 T2D patients versus 109 sex- and age-matched controls. Patients showed increases in glucose, insulin, homeostasis model assessment of insulin resistance, and glycated hemoglobin (HbA1c) compared with controls (p < 0.001). Leukocytes displayed enhanced total and mitochondrial reactive oxygen species (ROS), reduced mitochondrial mass, and increased chromatin condensation (p < 0.05). ER stress was also activated in diabetic patients, who displayed augmented glucose-regulated protein 78 kDa (GRP78), phosphorylated eukaryotic translation initiation factor 2, subunit 1 alpha (P-eIF2α), and activating transcription factor 6 (ATF6) levels (p < 0.05). We also observed an increase in the autophagy markers, microtubule-associated protein light chain 3 (LC3)-II and Beclin 1 (p < 0.05), and significant positive correlations between Beclin 1 and total ROS (r = 0.667), GRP78 (r = 0.925) and P-eIF2α (r = 0.644), and between LC3-II and P-eIF2α (r = 0.636) and ATF6 (r = 0.601). Our results lead to the hypothesis that autophagy is activated in the leukocytes of T2D patients and that both oxidative and ER stress signaling pathways may be implicated in the induction of autophagy.
Collapse
Affiliation(s)
- Susana Rovira-Llopis
- 1 Service of Endocrinology, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), University Hospital Doctor Peset , Valencia, Spain
- 2 Institute of Health Research INCLIVA, University of Valencia , Valencia, Spain
| | - Noelia Díaz-Morales
- 1 Service of Endocrinology, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), University Hospital Doctor Peset , Valencia, Spain
| | - Celia Bañuls
- 1 Service of Endocrinology, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), University Hospital Doctor Peset , Valencia, Spain
- 2 Institute of Health Research INCLIVA, University of Valencia , Valencia, Spain
| | - Ana Blas-García
- 1 Service of Endocrinology, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), University Hospital Doctor Peset , Valencia, Spain
- 3 CIBERehd-Department of Pharmacology and Physiology, University of Valencia , Valencia, Spain
| | - Miriam Polo
- 1 Service of Endocrinology, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), University Hospital Doctor Peset , Valencia, Spain
- 3 CIBERehd-Department of Pharmacology and Physiology, University of Valencia , Valencia, Spain
| | - Sandra López-Domenech
- 1 Service of Endocrinology, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), University Hospital Doctor Peset , Valencia, Spain
| | - Ana Jover
- 1 Service of Endocrinology, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), University Hospital Doctor Peset , Valencia, Spain
| | - Milagros Rocha
- 1 Service of Endocrinology, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), University Hospital Doctor Peset , Valencia, Spain
- 2 Institute of Health Research INCLIVA, University of Valencia , Valencia, Spain
- 3 CIBERehd-Department of Pharmacology and Physiology, University of Valencia , Valencia, Spain
| | - Antonio Hernández-Mijares
- 1 Service of Endocrinology, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), University Hospital Doctor Peset , Valencia, Spain
- 2 Institute of Health Research INCLIVA, University of Valencia , Valencia, Spain
- 4 Department of Medicine, University of Valencia , Valencia, Spain
| | - Víctor M Víctor
- 1 Service of Endocrinology, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), University Hospital Doctor Peset , Valencia, Spain
- 2 Institute of Health Research INCLIVA, University of Valencia , Valencia, Spain
- 3 CIBERehd-Department of Pharmacology and Physiology, University of Valencia , Valencia, Spain
- 5 Department of Physiology, University of Valencia , Valencia, Spain
| |
Collapse
|
52
|
Victor VM, Rovira-Llopis S, Bañuls C, Diaz-Morales N, Castelló R, Falcón R, Gómez M, Rocha M, Hernández-Mijares A. Effects of metformin on mitochondrial function of leukocytes from polycystic ovary syndrome patients with insulin resistance. Eur J Endocrinol 2015; 173:683-691. [PMID: 26320144 DOI: 10.1530/eje-15-0572] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/08/2015] [Accepted: 08/27/2015] [Indexed: 12/22/2022]
Abstract
OBJECTIVE Oxidative stress and mitochondrial dysfunction are implicated in polycystic ovary syndrome (PCOS). The present study assesses the effect of metformin treatment on mitochondrial function in polymorphonuclear cells from PCOS subjects. Additionally, we evaluate endocrine parameters and levels of interleukin 6 (IL6) and tumour necrosis factor alpha (TNFα). DESIGN AND METHODS Our study population was comprised of 35 women of reproductive age diagnosed with PCOS and treated with metformin for 12 weeks, and their corresponding controls (n=41), adjusted by age and BMI. We evaluated the alteration of endocrinological and anthropometrical parameters and androgen levels. Mitochondrial O2 consumption (using a Clark-type O2 electrode), membrane potential, mitochondrial mass, and levels of reactive oxygen species (ROS) and glutathione (GSH) (by means of fluorescence microscopy) were assessed in poymorphonuclear cells. H2O2 was evaluated with the Amplex Red(R) H2O2/Peroxidase Assay kit. IL6 and TNFα were measured using the Luminex 200 flow analyser system. RESULTS Metformin had beneficial effects on patients by increasing mitochondrial O2 consumption, membrane potential, mitochondrial mass and glutathione levels, and by decreasing levels of reactive oxygen species and H2O2. In addition, metformin reduced glucose, follicle-stimulating hormone, IL6 and TNFα levels and increased dehydroepiandrosterone sulfate levels. HOMA-IR and mitochondrial function biomarkers positively correlated with ROS production (r=0.486, P=0.025), GSH content (r=0.710, P=0.049) and H2O2 (r=0.837, P=0.010), and negatively correlated with membrane potential (r=-0.829, P=0.011) at baseline. These differences disappeared after metformin treatment. CONCLUSIONS Our results demonstrate the beneficial effects of metformin treatment on mitochondrial function in leukocytes of PCOS patients.
Collapse
Affiliation(s)
- Victor M Victor
- Service of EndocrinologyUniversity Hospital Doctor Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Avenida Gaspar Aguilar 90, 46017 Valencia, SpainInstitute of Health Research INCLIVAUniversity of Valencia, Valencia, SpainCIBERehd - Department of Pharmacology and PhysiologyUniversity of Valencia, Valencia, SpainDepartment of MedicineUniversity of Valencia, Valencia, Spain Service of EndocrinologyUniversity Hospital Doctor Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Avenida Gaspar Aguilar 90, 46017 Valencia, SpainInstitute of Health Research INCLIVAUniversity of Valencia, Valencia, SpainCIBERehd - Department of Pharmacology and PhysiologyUniversity of Valencia, Valencia, SpainDepartment of MedicineUniversity of Valencia, Valencia, Spain Service of EndocrinologyUniversity Hospital Doctor Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Avenida Gaspar Aguilar 90, 46017 Valencia, SpainInstitute of Health Research INCLIVAUniversity of Valencia, Valencia, SpainCIBERehd - Department of Pharmacology and PhysiologyUniversity of Valencia, Valencia, SpainDepartment of MedicineUniversity of Valencia, Valencia, Spain
| | - Susana Rovira-Llopis
- Service of EndocrinologyUniversity Hospital Doctor Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Avenida Gaspar Aguilar 90, 46017 Valencia, SpainInstitute of Health Research INCLIVAUniversity of Valencia, Valencia, SpainCIBERehd - Department of Pharmacology and PhysiologyUniversity of Valencia, Valencia, SpainDepartment of MedicineUniversity of Valencia, Valencia, Spain Service of EndocrinologyUniversity Hospital Doctor Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Avenida Gaspar Aguilar 90, 46017 Valencia, SpainInstitute of Health Research INCLIVAUniversity of Valencia, Valencia, SpainCIBERehd - Department of Pharmacology and PhysiologyUniversity of Valencia, Valencia, SpainDepartment of MedicineUniversity of Valencia, Valencia, Spain
| | - Celia Bañuls
- Service of EndocrinologyUniversity Hospital Doctor Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Avenida Gaspar Aguilar 90, 46017 Valencia, SpainInstitute of Health Research INCLIVAUniversity of Valencia, Valencia, SpainCIBERehd - Department of Pharmacology and PhysiologyUniversity of Valencia, Valencia, SpainDepartment of MedicineUniversity of Valencia, Valencia, Spain Service of EndocrinologyUniversity Hospital Doctor Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Avenida Gaspar Aguilar 90, 46017 Valencia, SpainInstitute of Health Research INCLIVAUniversity of Valencia, Valencia, SpainCIBERehd - Department of Pharmacology and PhysiologyUniversity of Valencia, Valencia, SpainDepartment of MedicineUniversity of Valencia, Valencia, Spain
| | - Noelia Diaz-Morales
- Service of EndocrinologyUniversity Hospital Doctor Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Avenida Gaspar Aguilar 90, 46017 Valencia, SpainInstitute of Health Research INCLIVAUniversity of Valencia, Valencia, SpainCIBERehd - Department of Pharmacology and PhysiologyUniversity of Valencia, Valencia, SpainDepartment of MedicineUniversity of Valencia, Valencia, Spain
| | - Raquel Castelló
- Service of EndocrinologyUniversity Hospital Doctor Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Avenida Gaspar Aguilar 90, 46017 Valencia, SpainInstitute of Health Research INCLIVAUniversity of Valencia, Valencia, SpainCIBERehd - Department of Pharmacology and PhysiologyUniversity of Valencia, Valencia, SpainDepartment of MedicineUniversity of Valencia, Valencia, Spain
| | - Rosa Falcón
- Service of EndocrinologyUniversity Hospital Doctor Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Avenida Gaspar Aguilar 90, 46017 Valencia, SpainInstitute of Health Research INCLIVAUniversity of Valencia, Valencia, SpainCIBERehd - Department of Pharmacology and PhysiologyUniversity of Valencia, Valencia, SpainDepartment of MedicineUniversity of Valencia, Valencia, Spain
| | - Marcelino Gómez
- Service of EndocrinologyUniversity Hospital Doctor Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Avenida Gaspar Aguilar 90, 46017 Valencia, SpainInstitute of Health Research INCLIVAUniversity of Valencia, Valencia, SpainCIBERehd - Department of Pharmacology and PhysiologyUniversity of Valencia, Valencia, SpainDepartment of MedicineUniversity of Valencia, Valencia, Spain
| | - Milagros Rocha
- Service of EndocrinologyUniversity Hospital Doctor Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Avenida Gaspar Aguilar 90, 46017 Valencia, SpainInstitute of Health Research INCLIVAUniversity of Valencia, Valencia, SpainCIBERehd - Department of Pharmacology and PhysiologyUniversity of Valencia, Valencia, SpainDepartment of MedicineUniversity of Valencia, Valencia, Spain Service of EndocrinologyUniversity Hospital Doctor Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Avenida Gaspar Aguilar 90, 46017 Valencia, SpainInstitute of Health Research INCLIVAUniversity of Valencia, Valencia, SpainCIBERehd - Department of Pharmacology and PhysiologyUniversity of Valencia, Valencia, SpainDepartment of MedicineUniversity of Valencia, Valencia, Spain Service of EndocrinologyUniversity Hospital Doctor Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Avenida Gaspar Aguilar 90, 46017 Valencia, SpainInstitute of Health Research INCLIVAUniversity of Valencia, Valencia, SpainCIBERehd - Department of Pharmacology and PhysiologyUniversity of Valencia, Valencia, SpainDepartment of MedicineUniversity of Valencia, Valencia, Spain
| | - Antonio Hernández-Mijares
- Service of EndocrinologyUniversity Hospital Doctor Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Avenida Gaspar Aguilar 90, 46017 Valencia, SpainInstitute of Health Research INCLIVAUniversity of Valencia, Valencia, SpainCIBERehd - Department of Pharmacology and PhysiologyUniversity of Valencia, Valencia, SpainDepartment of MedicineUniversity of Valencia, Valencia, Spain Service of EndocrinologyUniversity Hospital Doctor Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Avenida Gaspar Aguilar 90, 46017 Valencia, SpainInstitute of Health Research INCLIVAUniversity of Valencia, Valencia, SpainCIBERehd - Department of Pharmacology and PhysiologyUniversity of Valencia, Valencia, SpainDepartment of MedicineUniversity of Valencia, Valencia, Spain Service of EndocrinologyUniversity Hospital Doctor Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Avenida Gaspar Aguilar 90, 46017 Valencia, SpainInstitute of Health Research INCLIVAUniversity of Valencia, Valencia, SpainCIBERehd - Department of Pharmacology and PhysiologyUniversity of Valencia, Valencia, SpainDepartment of MedicineUniversity of Valencia, Valencia, Spain
| |
Collapse
|
53
|
Victor VM, Rovira-Llopis S, Bañuls C, Diaz-Morales N, Lopez-Domenech S, Escribano-López I, Rios-Navarro C, Alvarez A, Gomez M, Rocha M, Hernandez-Mijares A. Metformin modulates human leukocyte/endothelial cell interactions and proinflammatory cytokines in polycystic ovary syndrome patients. Atherosclerosis 2015; 242:167-173. [PMID: 26188541 DOI: 10.1016/j.atherosclerosis.2015.07.017] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/07/2015] [Revised: 06/17/2015] [Accepted: 07/07/2015] [Indexed: 10/23/2022]
Abstract
OBJECTIVE We aim to assess the effect of metformin treatment on metabolic parameters, endothelial function and inflammatory markers in polycystic ovary syndrome (PCOS) subjects. METHODS The study population consisted of 40 reproductive-age women with PCOS, who underwent treatment with metformin during a 12-week period, and their corresponding matched controls (n = 44). We evaluated endocrinological parameters, adhesion molecules (vascular cell adhesion molecule 1 (VCAM-1), intercellular cell adhesion molecule 1 (ICAM-1) and E-selectin) and proinflammatory cytokines (interleukin 6 (IL-6) and tumor necrosis factor alpha (TNFα)) in serum. In addition, interactions between human umbilical vein endothelial cells and polymorphonuclear (PMN) cells were assessed by flow chamber microscopy. In addition, a group of type 2 diabetes patients who underwent treatment with metformin during a 12-week period was incorporated into the study. RESULTS Metformin produced beneficial effects on PCOS patients by decreasing polymorphonuclear (PMN) rolling flux and adhesion. It also decreased levels of ICAM-1, E-selectin, IL-6 and ΤΝFα. In addition, metformin induced an improvement of endocrine and anthropometric parameters in PCOS subjects by reducing glucose, follicle-stimulating hormone (FSH) and androstendione, and by increasing dehydroepiandrosterone-sulfate (DHEA-S). Metformin also had beneficial effects in type 2 diabetic subjects by reducing body weight, waist circumference and PMN adhesion, and by increasing PMN rolling velocity. CONCLUSION Our results highlight the modulating effect of metformin on leukocyte/endothelium interactions. These findings may explain the potential beneficial effect of metformin in reducing the risk of vascular events in PCOS patients and in insulin resistance conditions.
Collapse
Affiliation(s)
- Victor M Victor
- Service of Endocrinology, University Hospital Dr. Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Valencia, Spain; Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain; Department of Physiology, University of Valencia, Valencia, Spain; Department of Pharmacology and CIBERehd, Faculty of Medicine, University of Valencia, Spain.
| | - Susana Rovira-Llopis
- Service of Endocrinology, University Hospital Dr. Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Valencia, Spain; Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain
| | - Celia Bañuls
- Service of Endocrinology, University Hospital Dr. Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Valencia, Spain; Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain
| | - Noelia Diaz-Morales
- Service of Endocrinology, University Hospital Dr. Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Valencia, Spain
| | - Sandra Lopez-Domenech
- Service of Endocrinology, University Hospital Dr. Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Valencia, Spain
| | - Irene Escribano-López
- Service of Endocrinology, University Hospital Dr. Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Valencia, Spain
| | - Cesar Rios-Navarro
- Service of Endocrinology, University Hospital Dr. Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Valencia, Spain; Department of Pharmacology and CIBERehd, Faculty of Medicine, University of Valencia, Spain
| | - Angeles Alvarez
- Department of Pharmacology and CIBERehd, Faculty of Medicine, University of Valencia, Spain; Fundación General de Universidad de Valencia, Valencia, Spain
| | - Marcelino Gomez
- Service of Endocrinology, University Hospital Dr. Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Valencia, Spain; Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain
| | - Milagros Rocha
- Service of Endocrinology, University Hospital Dr. Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Valencia, Spain; Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain; Department of Pharmacology and CIBERehd, Faculty of Medicine, University of Valencia, Spain.
| | - Antonio Hernandez-Mijares
- Service of Endocrinology, University Hospital Dr. Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Valencia, Spain; Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain; Department of Medicine, University of Valencia, Valencia, Spain.
| |
Collapse
|
54
|
Víctor VM, Rovira-Llopis S, Saiz-Alarcón V, Sangüesa MC, Rojo-Bofill L, Bañuls C, de Pablo C, Álvarez Á, Rojo L, Rocha M, Hernández-Mijares A. Involvement of leucocyte/endothelial cell interactions in anorexia nervosa. Eur J Clin Invest 2015; 45:670-678. [PMID: 25944525 DOI: 10.1111/eci.12454] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/30/2014] [Accepted: 04/22/2015] [Indexed: 12/15/2022]
Abstract
BACKGROUND Anorexia nervosa is a common psychiatric disorder in adolescence and is related to cardiovascular complications. Our aim was to study the effect of anorexia nervosa on metabolic parameters, leucocyte-endothelium interactions, adhesion molecules and proinflammatory cytokines. MATERIALS AND METHODS This multicentre, cross-sectional, case-control study employed a population of 24 anorexic female patients and 36 controls. We evaluated anthropometric and metabolic parameters, interactions between leucocytes polymorphonuclear neutrophils (PMN) and human umbilical vein endothelial cells (HUVEC), proinflammatory cytokines such as tumour necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) and soluble cellular adhesion molecules (CAMs) including E-selectin, vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1). RESULTS Anorexia nervosa was related to a decrease in weight, body mass index, waist circumference, systolic blood pressure, glucose, insulin and HOMA-IR, and an increase in HDL cholesterol. These effects disappeared after adjusting for BMI. Anorexia nervosa induced a decrease in PMN rolling velocity and an increase in PMN rolling flux and PMN adhesion. Increases in IL-6 and TNF-α and adhesion molecule VCAM-1 were also observed. CONCLUSIONS This study supports the hypothesis of an association between anorexia nervosa, inflammation and the induction of leucocyte-endothelium interactions. These findings may explain, in part at least, the increased risk of vascular disease among patients with anorexia nervosa.
Collapse
Affiliation(s)
- Víctor M Víctor
- Foundation for the Promotion of Healthcare and Biomedical Research in the Valencian Community (FISABIO), Valencia, Spain
- Service of Endocrinology, University Hospital Doctor Peset, Valencia, Spain
- Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain
- Department of Physiology, University of Valencia, Valencia, Spain
| | - Susana Rovira-Llopis
- Foundation for the Promotion of Healthcare and Biomedical Research in the Valencian Community (FISABIO), Valencia, Spain
- Service of Endocrinology, University Hospital Doctor Peset, Valencia, Spain
- Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain
| | | | | | | | - Celia Bañuls
- Foundation for the Promotion of Healthcare and Biomedical Research in the Valencian Community (FISABIO), Valencia, Spain
- Service of Endocrinology, University Hospital Doctor Peset, Valencia, Spain
- Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain
| | - Carmen de Pablo
- Department of Pharmacology and CIBER CB06/04/0071 Research Group, CIBER Hepatic and Digestive Diseases, University of Valencia, Valencia, Spain
| | - Ángeles Álvarez
- Department of Pharmacology and CIBER CB06/04/0071 Research Group, CIBER Hepatic and Digestive Diseases, University of Valencia, Valencia, Spain
- Fundacion General de la Universidad de Valencia, Valencia, Spain
| | - Luis Rojo
- Psychiatry Service, University Hospital La Fe, Valencia, Spain
- Research Group CIBER CB/06/02/0045 CIBER actions - Epidemiology and Public Health, University of Valencia, Valencia, Spain
- Department of Medicine, University of Valencia, Valencia, Spain
| | - Milagros Rocha
- Foundation for the Promotion of Healthcare and Biomedical Research in the Valencian Community (FISABIO), Valencia, Spain
- Service of Endocrinology, University Hospital Doctor Peset, Valencia, Spain
- Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain
| | - Antonio Hernández-Mijares
- Foundation for the Promotion of Healthcare and Biomedical Research in the Valencian Community (FISABIO), Valencia, Spain
- Service of Endocrinology, University Hospital Doctor Peset, Valencia, Spain
- Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain
- Department of Medicine, University of Valencia, Valencia, Spain
| |
Collapse
|
55
|
Rovira-Llopis S, Bañuls C, Apostolova N, Morillas C, Hernandez-Mijares A, Rocha M, Victor VM. Is glycemic control modulating endoplasmic reticulum stress in leukocytes of type 2 diabetic patients? Antioxid Redox Signal 2014; 21:1759-1765. [PMID: 25000244 DOI: 10.1089/ars.2014.6030] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Oxidative and endoplasmic reticulum (ER) stress is related to type 2 diabetes (T2D), but the influence of glycemic control on these parameters and its relationship with leukocyte-endothelial interactions is not known. In our study population consisting of 164 diabetic patients, (102 with glycated hemoglobin [HbA1c] <7% and 62 with HbA1c >7%) and 84 nondiabetic controls, we have verified a common anthropometric and metabolic pattern of T2D with dyslipidemia. Inflammatory parameters (high-sensitive C-reactive protein [hs-CRP] and tumor necrosis factor alpha [TNFα]) and E-selectin levels were enhanced in the HbA1c >7% group with regard to controls. O2 consumption and mitochondrial membrane potential were lower in diabetic patients than in controls. Reactive oxygen species (ROS) production was enhanced in diabetic patients than in controls and positively correlated with HbA1c levels. GRP78 levels were higher in both diabetic groups. However, HbA1c <7% patients displayed higher levels of spliced X-box binding protein 1 (sXBP1), whereas HbA1c >7% patients exhibited preferentially enhanced levels of CHOP (CCAAT/enhancer binding protein [C/EBP] homologous protein) and activating transcription factor 6 (ATF6). Reduced leukocyte rolling velocity and increased rolling flux and adhesion were observed in diabetic patients. Our findings lead to the hypothesis of an association between poor glycemic control in T2D and increased leukocyte ROS production and chronic ER stress that could finally promote leukocyte-endothelial interactions, which, in turn, poses a risk of vascular complications for these patients.
Collapse
Affiliation(s)
- Susana Rovira-Llopis
- 1 Foundation for the Promotion of Healthcare and Biomedical Research in the Valencian Community (FISABIO) , Valencia, Spain
| | | | | | | | | | | | | |
Collapse
|
56
|
Polycystic Ovary Syndrome as a Paradigm for Prehypertension, Prediabetes, and Preobesity. Curr Hypertens Rep 2014; 16:500. [DOI: 10.1007/s11906-014-0500-6] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|
57
|
Victor VM, Rovira-Llopis S, Saiz-Alarcon V, Sangüesa MC, Rojo-Bofill L, Bañuls C, Falcón R, Castelló R, Rojo L, Rocha M, Hernández-Mijares A. Altered mitochondrial function and oxidative stress in leukocytes of anorexia nervosa patients. PLoS One 2014; 9:e106463. [PMID: 25254642 PMCID: PMC4177818 DOI: 10.1371/journal.pone.0106463] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2014] [Accepted: 08/06/2014] [Indexed: 11/23/2022] Open
Abstract
CONTEXT Anorexia nervosa is a common illness among adolescents and is characterised by oxidative stress. OBJECTIVE The effects of anorexia on mitochondrial function and redox state in leukocytes from anorexic subjects were evaluated. DESIGN AND SETTING A multi-centre, cross-sectional case-control study was performed. PATIENTS Our study population consisted of 20 anorexic patients and 20 age-matched controls, all of which were Caucasian women. MAIN OUTCOME MEASURES Anthropometric and metabolic parameters were evaluated in the study population. To assess whether anorexia nervosa affects mitochondrial function and redox state in leukocytes of anorexic patients, we measured mitochondrial oxygen consumption, membrane potential, reactive oxygen species production, glutathione levels, mitochondrial mass, and complex I and III activity in polymorphonuclear cells. RESULTS Mitochondrial function was impaired in the leukocytes of the anorexic patients. This was evident in a decrease in mitochondrial O2 consumption (P<0.05), mitochondrial membrane potential (P<0.01) and GSH levels (P<0.05), and an increase in ROS production (P<0.05) with respect to control subjects. Furthermore, a reduction of mitochondrial mass was detected in leukocytes of the anorexic patients (P<0.05), while the activity of mitochondrial complex I (P<0.001), but not that of complex III, was found to be inhibited in the same population. CONCLUSIONS Oxidative stress is produced in the leukocytes of anorexic patients and is closely related to mitochondrial dysfunction. Our results lead us to propose that the oxidative stress that occurs in anorexia takes place at mitochondrial complex I. Future research concerning mitochondrial dysfunction and oxidative stress should aim to determine the physiological mechanism involved in this effect and the physiological impact of anorexia.
Collapse
Affiliation(s)
- Victor M. Victor
- Foundation for the Promotion of Healthcare and Biomedical Research in the Valencian Community (FISABIO), Valencia, Spain
- Service of Endocrinology, University Hospital Doctor Peset, Valencia, Spain
- Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain
| | - Susana Rovira-Llopis
- Foundation for the Promotion of Healthcare and Biomedical Research in the Valencian Community (FISABIO), Valencia, Spain
- Service of Endocrinology, University Hospital Doctor Peset, Valencia, Spain
- Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain
| | - Vanessa Saiz-Alarcon
- Psychiatry Service, University Hospital La Fe, Department of Medicine, University of Valencia, Valencia, Spain
| | - Maria C. Sangüesa
- Psychiatry Service, University Hospital La Fe, Department of Medicine, University of Valencia, Valencia, Spain
| | - Luis Rojo-Bofill
- Psychiatry Service, University Hospital La Fe, Department of Medicine, University of Valencia, Valencia, Spain
| | - Celia Bañuls
- Foundation for the Promotion of Healthcare and Biomedical Research in the Valencian Community (FISABIO), Valencia, Spain
- Service of Endocrinology, University Hospital Doctor Peset, Valencia, Spain
- Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain
| | - Rosa Falcón
- Foundation for the Promotion of Healthcare and Biomedical Research in the Valencian Community (FISABIO), Valencia, Spain
- Service of Endocrinology, University Hospital Doctor Peset, Valencia, Spain
- Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain
| | - Raquel Castelló
- Foundation for the Promotion of Healthcare and Biomedical Research in the Valencian Community (FISABIO), Valencia, Spain
- Service of Endocrinology, University Hospital Doctor Peset, Valencia, Spain
- Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain
| | - Luis Rojo
- Psychiatry Service, University Hospital La Fe, Department of Medicine, University of Valencia, Valencia, Spain
- Research Group CIBER CB/06/02/0045, CIBER actions, Epidemiology and Public Health, University of Valencia, Valencia, Spain
| | - Milagros Rocha
- Foundation for the Promotion of Healthcare and Biomedical Research in the Valencian Community (FISABIO), Valencia, Spain
- Service of Endocrinology, University Hospital Doctor Peset, Valencia, Spain
- Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain
| | - Antonio Hernández-Mijares
- Foundation for the Promotion of Healthcare and Biomedical Research in the Valencian Community (FISABIO), Valencia, Spain
- Service of Endocrinology, University Hospital Doctor Peset, Valencia, Spain
- Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain
- Department of Medicine, University of Valencia, Valencia, Spain
| |
Collapse
|
58
|
Tang X, Luo YX, Chen HZ, Liu DP. Mitochondria, endothelial cell function, and vascular diseases. Front Physiol 2014; 5:175. [PMID: 24834056 PMCID: PMC4018556 DOI: 10.3389/fphys.2014.00175] [Citation(s) in RCA: 268] [Impact Index Per Article: 24.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2014] [Accepted: 04/16/2014] [Indexed: 12/20/2022] Open
Abstract
Mitochondria are perhaps the most sophisticated and dynamic responsive sensing systems in eukaryotic cells. The role of mitochondria goes beyond their capacity to create molecular fuel and includes the generation of reactive oxygen species, the regulation of calcium, and the activation of cell death. In endothelial cells, mitochondria have a profound impact on cellular function under both healthy and diseased conditions. In this review, we summarize the basic functions of mitochondria in endothelial cells and discuss the roles of mitochondria in endothelial dysfunction and vascular diseases, including atherosclerosis, diabetic vascular dysfunction, pulmonary artery hypertension, and hypertension. Finally, the potential therapeutic strategies to improve mitochondrial function in endothelial cells and vascular diseases are also discussed, with a focus on mitochondrial-targeted antioxidants and calorie restriction.
Collapse
Affiliation(s)
- Xiaoqiang Tang
- State Key Laboratory of Medical Molecular Biology, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing, China
| | - Yu-Xuan Luo
- State Key Laboratory of Medical Molecular Biology, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing, China
| | - Hou-Zao Chen
- State Key Laboratory of Medical Molecular Biology, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing, China
| | - De-Pei Liu
- State Key Laboratory of Medical Molecular Biology, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing, China
| |
Collapse
|
59
|
Victor VM, Rocha M, Bañuls C, Rovira-Llopis S, Gómez M, Hernández-Mijares A. Mitochondrial impairment and oxidative stress in leukocytes after testosterone administration to female-to-male transsexuals. J Sex Med 2014; 11:454-461. [PMID: 24251401 DOI: 10.1111/jsm.12376] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
INTRODUCTION Testosterone undecanoate (T) treatment is common in female-to-male transsexuals (FtMs) but can induce impairment of mitochondrial function and oxidative stress. AIM The effect of T treatment on the mitochondrial function and redox state of leukocytes of FtMs subjects was evaluated. METHODS This was an observational study conducted in a university hospital. Fifty-seven FtMs were treated with T (1,000 mg) for 12 weeks, after which anthropometric and metabolic parameters and mitochondrial function were evaluated. MAIN OUTCOME MEASURES Anthropometric and metabolic parameters were evaluated. Mitochondrial function was studied by assessing mitochondrial oxygen (O2) consumption, membrane potential, reactive oxygen species (ROS) production, glutathione levels (GSH), and the reduced glutathione/oxidized glutathione (GSH)/(GSSG) ratio in polymorphonuclear cells. RESULTS T treatment led to mitochondrial impairment in FtMs as a result of a decrease in mitochondria O2 consumption, the membrane potential, GSH levels, and the (GSH)/(GSSG) ratio and an increase in ROS production. Mitochondrial O2 consumption and membrane potential negatively correlated with T levels, which was further confirmed that the T treatment had induced mitochondrial dysfunction. T also produced a significant increase in total testosterone, free androgenic index, and atherogenic index of plasma, and a decrease in sex hormone-binding globulin and high-density lipoprotein cholesterol. CONCLUSIONS Treatment of FtMs with T can induce impairment of mitochondrial function and a state of oxidative stress. This effect should be taken into account in order to modulate possible comorbidities in these patients.
Collapse
Affiliation(s)
- Víctor M Victor
- Endocrinology Service, Foundation for the Promotion of Healthcare and Biomedical Research in the Valencian Community (FISABIO), University Hospital Doctor Peset, Valencia, Spain; Endocrinology Service, University Hospital Doctor Peset, Valencia, Spain; Institute of Health Research INCLIVA, Valencia, Spain; Department of Pharmacology and CIBER CB06/04/0071 Research Group, CIBER Hepatic and Digestive Diseases, University of Valencia, Valencia, Spain; Department of Physiology, Faculty of Medicine, University of Valencia, Valencia, Spain
| | | | | | | | | | | |
Collapse
|
60
|
Rocha M, Apostolova N, Herance JR, Rovira-Llopis S, Hernandez-Mijares A, Victor VM. Perspectives and potential applications of mitochondria-targeted antioxidants in cardiometabolic diseases and type 2 diabetes. Med Res Rev 2014; 34:160-189. [PMID: 23650093 DOI: 10.1002/med.21285] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
There is abundant evidence to suggest that mitochondrial dysfunction is a main cause of insulin resistance and related cardiometabolic comorbidities. On the other hand, insulin resistance is one of the main characteristics of type 2 diabetes, obesity, and metabolic syndrome. Lipid and glucose metabolism require mitochondria to generate energy, and when O2 consumption is low due to inefficient nutrient oxidation, there is an increase in reactive oxygen species, which can impair different types of molecules, including DNA, lipids, proteins, and carbohydrates, thereby inducing proinflammatory processes. Factors which contribute to mitochondrial dysfunction, such as mitochondrial biogenesis and genetics, can also lead to insulin resistance in different insulin-target tissues, and its association with mitochondrial dysfunction can culminate in the development of cardiovascular diseases. In this context, therapies that improve mitochondrial function may also improve insulin resistance. This review explains mechanisms of mitochondrial function related to the pathological effects of insulin resistance in different tissues. The pathogenesis of cardiometabolic diseases will be explained from a mitochondrial perspective and the potential beneficial effects of mitochondria-targeted antioxidants as a therapy for modulating mitochondrial function in cardiometabolic diseases, especially diabetes, will also be considered.
Collapse
Affiliation(s)
- Milagros Rocha
- Fundacion para la Investigacion Sanitaria y Biomedica de la Comunidad Valenciana FISABIO, Valencia, Spain; University Hospital Doctor Peset, Endocrinology Service, Valencia, Spain; INCLIVA Foundation, Valencia, Spain
| | | | | | | | | | | |
Collapse
|
61
|
Rovira-Llopis S, Rocha M, Falcon R, de Pablo C, Alvarez A, Jover A, Hernandez-Mijares A, Victor VM. Is myeloperoxidase a key component in the ROS-induced vascular damage related to nephropathy in type 2 diabetes? Antioxid Redox Signal 2013; 19:1452-1458. [PMID: 23521574 PMCID: PMC3797450 DOI: 10.1089/ars.2013.5307] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/18/2013] [Accepted: 03/24/2013] [Indexed: 11/13/2022]
Abstract
It is still unclear whether microvascular complications of type 2 diabetes correlate with leukocyte-endothelium interactions and/or myeloperoxidase (MPO) levels. In the present study, we found that serum levels of glucose, the rate of ROS and MPO concentration were higher in type 2 diabetic patients. Patients with nephropathy (39.6%) presented higher MPO levels that correlate positively with the albumin/creatinine ratio (r = 0.59, p<0.05). In addition, nephropatic patients showed increased leukocyte-endothelium interactions due to an undermining of polymorphonuclear leukocytes (PMN) rolling velocity and increased rolling flux and adhesion, which was accompanied by a rise in levels of the proinflammatory cytokine tumour necrosis factor alpha (TNFα) and the adhesion molecule E-selectin. Furthermore, MPO levels were positively correlated with PMN rolling flux (r = 0.855, p < 0.01) and adhesion (r = 0.682, p<0.05). Our results lead to the hypothesis that type 2 diabetes induces oxidative stress and an increase in MPO levels and leukocyte-endothelium interactions, and that these effects correlate with the development of nephropathy.
Collapse
Affiliation(s)
- Susana Rovira-Llopis
- Fundacion para la Investigacion Sanitaria y Biomedica de la Comunidad Valenciana FISABIO, Endocrinology Service, University Hospital Doctor Peset, Valencia, Spain
- Endocrinology Service, University Hospital Doctor Peset, Valencia, Spain
| | - Milagros Rocha
- Fundacion para la Investigacion Sanitaria y Biomedica de la Comunidad Valenciana FISABIO, Endocrinology Service, University Hospital Doctor Peset, Valencia, Spain
- Endocrinology Service, University Hospital Doctor Peset, Valencia, Spain
- Fundacion para la Investigación (INCLIVA), Universidad de Valencia, Valencia, Spain
| | - Rosa Falcon
- Fundacion para la Investigacion Sanitaria y Biomedica de la Comunidad Valenciana FISABIO, Endocrinology Service, University Hospital Doctor Peset, Valencia, Spain
- Endocrinology Service, University Hospital Doctor Peset, Valencia, Spain
| | - Carmen de Pablo
- Department of Pharmacology and CIBER CB06/04/0071 Research Group, CIBER Hepatic and Digestive Diseases, University of Valencia, Valencia, Spain
| | - Angeles Alvarez
- Department of Pharmacology and CIBER CB06/04/0071 Research Group, CIBER Hepatic and Digestive Diseases, University of Valencia, Valencia, Spain
- Fundación General de la Universidad de Valencia, Valencia, Spain
| | - Ana Jover
- Endocrinology Service, University Hospital Doctor Peset, Valencia, Spain
| | - Antonio Hernandez-Mijares
- Fundacion para la Investigacion Sanitaria y Biomedica de la Comunidad Valenciana FISABIO, Endocrinology Service, University Hospital Doctor Peset, Valencia, Spain
- Endocrinology Service, University Hospital Doctor Peset, Valencia, Spain
- Fundacion para la Investigación (INCLIVA), Universidad de Valencia, Valencia, Spain
- Department of Medicine, University of Valencia, Valencia, Spain
| | - Victor M. Victor
- Fundacion para la Investigacion Sanitaria y Biomedica de la Comunidad Valenciana FISABIO, Endocrinology Service, University Hospital Doctor Peset, Valencia, Spain
- Endocrinology Service, University Hospital Doctor Peset, Valencia, Spain
- Fundacion para la Investigación (INCLIVA), Universidad de Valencia, Valencia, Spain
- Department of Physiology, University of Valencia, Valencia, Spain
| |
Collapse
|